246 related articles for article (PubMed ID: 27789082)
1. Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer.
Kim JY; Byun SJ; Kim YS; Nam JH
Gynecol Oncol; 2017 Jan; 144(1):34-39. PubMed ID: 27789082
[TBL] [Abstract][Full Text] [Related]
2. Cervical cancer response to neoadjuvant chemoradiotherapy: MRI assessment compared with surgery.
Gui B; Valentini AL; Miccò M; D'Agostino GR; Tagliaferri L; Zannoni GF; Fanfani F; Manfredi R; Bonomo L
Acta Radiol; 2016 Sep; 57(9):1123-31. PubMed ID: 26622060
[TBL] [Abstract][Full Text] [Related]
3. Use of Metabolic Parameters as Prognostic Factors During Concomitant Chemoradiotherapy for Locally Advanced Cervical Cancer.
Krhili S; Muratet JP; Roche S; Pointreau Y; Yossi S; Septans AL; Denis F
Am J Clin Oncol; 2017 Jun; 40(3):250-255. PubMed ID: 27028351
[TBL] [Abstract][Full Text] [Related]
4. Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.
Kim SW; Chun M; Ryu HS; Chang SJ; Kong TW; Lee EJ; Lee YH; Oh YT
Strahlenther Onkol; 2017 Jul; 193(7):534-542. PubMed ID: 28357468
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging after external beam radiotherapy and concurrent chemotherapy for locally advanced cervical cancer helps to identify patients at risk of recurrence.
Angeles MA; Baissas P; Leblanc E; Lusque A; Ferron G; Ducassou A; Martínez-Gómez C; Querleu D; Martinez A
Int J Gynecol Cancer; 2019 Mar; 29(3):480-486. PubMed ID: 30712019
[TBL] [Abstract][Full Text] [Related]
6. What to expect from immediate salvage hysterectomy following concomitant chemoradiation and image-guided adaptive brachytherapy in locally advanced cervical cancer.
Castelnau-Marchand P; Chargari C; Bouaita R; Dumas I; Farha G; Kamsu-Kom L; Rivin Del Campo E; Martinetti F; Morice P; Haie-Meder C; Mazeron R
Cancer Radiother; 2015 Dec; 19(8):710-7. PubMed ID: 26508320
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging during definitive chemoradiotherapy can predict tumor recurrence and patient survival in locally advanced cervical cancer: A multi-institutional retrospective analysis of KROG 16-01.
Lee SW; Lee SH; Kim J; Kim YS; Yoon MS; Jeong S; Kim JH; Lee J; Eom KY; Jeong BK; Sung SY; Lee SJ; Lee JH
Gynecol Oncol; 2017 Nov; 147(2):334-339. PubMed ID: 28935271
[TBL] [Abstract][Full Text] [Related]
9. Surgical morbidity and oncologic results after concurrent chemoradiation therapy for advanced cervical cancer.
Sun L; Sheng X; Jiang J; Li X; Liu N; Liu Y; Zhang T; Li D; Zhang X; Wei P
Int J Gynaecol Obstet; 2014 May; 125(2):111-5. PubMed ID: 24548892
[TBL] [Abstract][Full Text] [Related]
10. Three-Dimensional Power Doppler Ultrasound for Predicting Response and Local Recurrence After Concomitant Chemoradiation Therapy for Locally Advanced Carcinoma of the Cervix.
Alcazar JL; Arribas S; Martinez-Monge R; Jurado M
Int J Gynecol Cancer; 2016 Mar; 26(3):534-8. PubMed ID: 26745701
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer.
Park SH; Cheon H; Chong GO; Jeong SY; Lee JE; Kang MK; Kim MY; Lee JW; Park J; Kim JC
Gynecol Oncol; 2018 Mar; 148(3):449-455. PubMed ID: 29329882
[TBL] [Abstract][Full Text] [Related]
12. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
[TBL] [Abstract][Full Text] [Related]
13. Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy.
Shim SH; Lee SW; Park JY; Kim YS; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2013 Jan; 128(1):54-59. PubMed ID: 23063760
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study.
Hequet D; Marchand E; Place V; Fourchotte V; De La Rochefordière A; Dridi S; Coutant C; Lecuru F; Bats AS; Koskas M; Bretel JJ; Bricou A; Delpech Y; Barranger E
Eur J Surg Oncol; 2013 Dec; 39(12):1428-34. PubMed ID: 24183796
[TBL] [Abstract][Full Text] [Related]
15. Salvage surgery for patients with residual disease after chemoradiation therapy for locally advanced cervical cancer: A systematic review on indication, complications, and survival.
van Kol KGG; Ebisch RMF; Piek JMJ; Zusterzeel PLM; Vergeldt TFM; Bekkers RLM
Acta Obstet Gynecol Scand; 2021 Jul; 100(7):1176-1185. PubMed ID: 33469927
[TBL] [Abstract][Full Text] [Related]
16. Individualized pelvic lymphadenectomy should follow neoadjuvant concurrent chemoradiotherapy for locally advanced cervical cancer.
Wei LC; Li X; Zhang Y; Dang YZ; Li WW; Li JP; Zhao LN; Liu SJ; Li X; Shi M
Medicine (Baltimore); 2018 Apr; 97(14):e0331. PubMed ID: 29620659
[TBL] [Abstract][Full Text] [Related]
17. Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI.
Lee JE; Huh SJ; Nam H; Ju SG
Ann Nucl Med; 2013 Jan; 27(1):37-45. PubMed ID: 23054833
[TBL] [Abstract][Full Text] [Related]
18. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery.
Yang J; Yang J; Cao D; Shen K; Ma J; Zhang F
J Gynecol Oncol; 2020 Mar; 31(2):e16. PubMed ID: 31912674
[TBL] [Abstract][Full Text] [Related]
19. Comparison of positron emission tomography/computed tomography and magnetic resonance imaging for posttherapy evaluation in patients with advanced cervical cancer receiving definitive concurrent chemoradiotherapy.
Su TP; Lin G; Huang YT; Liu FY; Wang CC; Chao A; Chou HH; Yen TC; Lai CH
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):727-734. PubMed ID: 29159572
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage IB-IIB cervical cancer.
Lee J; Kim TH; Kim GE; Keum KC; Kim YB
J Gynecol Oncol; 2016 Sep; 27(5):e52. PubMed ID: 27329200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
